“…Censoring occurred at the time of death, switch to watchful waiting (ie, no active monitoring with noncurative treatment if symptoms arise), loss to follow-up, or the last follow-up date if still on AS. Models were adjusted for age (5-yr age groups), diagnostic period (1995–2004, 2005–2009, 2010–2014, and 2015–2018), diagnostic method (transrectal ultrasound guided biopsies, transperineal guided biopsies [TPs], and transurethral resection of the prostate [TURP]), and clinical characteristics at diagnosis—grade group (2 vs 1), clinical stage (T2 vs T1), PSA concentration (<5, 5–9.9, 10–14.9, and 15–20 ng/ml), prostate volume (continuous per 10 ng/cc [3] ), number of cores sampled (continuous), and number of positive cores (continuous). We assessed the risk of upgrading at any follow-up biopsy and the risk of potential disease progression among men who had undergone one or more repeat biopsies, using mixed-effects logistic regression, with random intercepts for treatment centre (level 2).…”